

A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients

Neeral L. Shah,* Patrick G. Northup,* Stephen H. Caldwell*

* University of Virginia Coagulation in Liver Disease Study Group. University of Virginia Medical Center Charlottesville, VA 22908. USA.

ABSTRACT

Background. The relative incidence of bleeding and thrombotic events and the use of blood products in hospitalized cirrhosis patients have not been widely reported. We aimed to estimate the magnitude of bleeding events and venous thrombosis in consecutive hospitalized cirrhotic patients over a finite time period and to examine the amount and indications for blood product use in cirrhosis patients admitted to a tertiary care center. **Results.** Among patients admitted with decompensated liver disease, 34 (40%) suffered bleeding events (about one-half non-variceal) and 6 patients (7%) suffered deep venous thrombosis. In the blood product survey, 168 patients were transfused with plasma or platelets during the survey intervals. Liver disease patients accounted for 7.7% of the total but disproportionately consumed 32.4% (46 of 142) of the units of plasma mostly administered as prophylaxis. In contrast, cirrhosis patients received only 7 of the 53 units of platelets transfused (13.2%) during the survey intervals. **Conclusions.** Coagulation issues constitute a common problem in patients with liver disease. Recent advances in laboratory testing have shown that stable cirrhosis patients are relatively hypercoagulable. The result of this prospective survey among decompensated (unstable) cirrhosis patients shows that, while DVT is not uncommon, bleeding (non-variceal in one half) remains the dominant clinical problem. This situation likely sustains the common practice of plasma infusion in these patients although its use is of unproven and questionable benefit. Better clinical tools are needed to refine clinical practice in this setting.

Key words. Blood bank. Plasma. Platelets. Cirrhosis. Transfusion.

INTRODUCTION

Chronic liver disease exerts a significant burden of care on the medical field.¹ Patients are often hospitalized for various complications related to their liver disease, and matters of coagulation or hemostasis often affect their course. Cirrhosis is characterized by complex hemostatic defects including thrombocytopenia, increased platelet adherence due to von Willebrand factor, reduced liver synthesized pro- and anti-coagulation factors, increased endothelial derived pro-coagulant factors such as

factor VIII and hyperfibrinolysis.²⁻⁷ These changes lead to increased bleeding risk and to the more recently recognized and somewhat paradoxical increased thrombotic risk.⁸⁻¹⁰ However, the magnitude of these opposing conditions among decompensated and hospitalized cirrhosis patients has not been well characterized especially in terms of the incidence and the effect of these problems on blood product use. As newer management strategies emerge to treat hemostatic problems in cirrhosis, it is important to better understand the relative impact of these conditions.

In this study, we aimed to estimate the incidence of bleeding and/or documented thrombotic episodes in a hospitalized liver disease population over a defined period of time. In a separate 'point in time' survey, we assessed the magnitude of plasma and platelets transfusions administered to patients with advanced liver disease patients in a tertiary care hospital. We did not seek to determine predictors of bleeding in this work, but rather we aimed more

Correspondence and reprint request: Dr. Neeral Shah, M.D.
Division of Gastroenterology/Hepatology, Department of Medicine, University of Virginia.
PO Box 800708, Charlottesville, VA 22908
Fax: 434-244-9415. Ph.: 434-924-0316
E mail: ns3zt@virginia.edu

Manuscript received: April 26, 2012.
Manuscript accepted: May 9, 2012.

simply to determine the magnitude of these opposing problems and the current use of blood products.

MATERIAL AND METHODS

We completed a prospective Quality Indicator Survey of the inpatient hepatology service from December 2009 to January 2010. Over a continuous 6-week period we monitored the inpatient Hepatology Service at the University of Virginia to identify episodes of bleeding or thrombotic problems among patients admitted with decompensated cirrhosis. Episodes of bleeding were defined as clinically apparent blood loss requiring intervention and included variceal bleeding or other gastrointestinal bleeding, mucosal bleeding, puncture wound bleeding, epistaxis, large, spontaneous internal hematomas or extensive external hematomas involving the majority of a limb or flank surface area and bleeding post-procedures such as dental extractions. Thrombotic events included peripheral and visceral deep vein thrombosis confirmed by radiographic imaging.

In a separate study performed over a randomly chosen 15-day period, medical center blood product use was surveyed on three non-consecutive days. The days were spaced (days 1, 7 and 15) to avoid patient overlap during longer hospitalizations. On each of these three days, we obtained blood bank records detailing fresh frozen plasma (FFP) and platelet transfusions. From these records, patients with liver disease were identified. We then determined the pre-transfusion indication, the amount of blood products given, and the subsequent clinical course. The liver disease patients' course was also assessed for two days post-transfusion to determine side-effects and outcomes.

RESULTS

Bleeding and thrombotic events in decompensated cirrhosis

Over the 6-week period, there were 85 admissions of decompensated cirrhosis to the inpatient service. A total of 34 of 85 patients (40%) suffered bleeding events during this time (Table 1). About one half were non-variceal. GI bleeding was the most common cause occurring in 23 patients with 14 episodes of variceal bleeding and 10 episodes of non-variceal GI bleeding. Non-variceal GI bleeding resulted from various causes including 3 portal hypertensive gastropathy bleeds, 3 Mallory Weiss tears, 2 peptic ulcer bleeds, 2 episodes of epistaxis, and 1

hemorrhoidal bleed (Table 1). As per our previously defined criteria for bleeding, all 34 patients with an event received some type of intervention, and many received multiple blood products and pro-coagulants: 91% of patients were transfused with packed red blood cells, 65% were transfused with platelets, and

Table 1. Bleeding and clotting events over 6 weeks (85 admissions).

• Bleeding events

Patient	Bleeding site
1	Dialysis catheter puncture site
2	Esophageal varices
3	Duodenal ulcer
4	Gastric antral vascular ectasia (GAVE)
5	Esophageal varices
6	Rectal bleeding
7	Portal hypertensive gastropathy
8	Esophageal varices
9	Mallory Weiss tear
10	Esophageal varices
11	Esophageal varices
12	Hemorrhoids
13	Esophageal varices
14	Gastric antral vascular ectasia (GAVE)
15	Portacath site hematoma
16	Esophageal varices
17	Epistaxis
18	Mallory Weiss tear
19	Ankle surgery bleeding
20	Epistaxis
21	Esophageal varices
22	Hematoma
23	Esophageal varices
24	Esophageal varices
25	Mallory Weiss tear
26	Hemoperitoneum s/p paracentesis
27	Esophageal varices
28	Rectal bleeding
29	Subdural hemorrhage
30	Ulcer bleed
31	Gastric varices
32	Gastric varices

• Clotting events

Patient	Clot type
33	Deep vein thrombosis
34	Deep vein thrombosis
35	Portal vein thrombosis
36	Deep vein thrombosis

• Bleeding and clotting events

Patient	Bleeding event and clot type
37	Gastric varices and deep vein thrombosis Hemoperitoneum post-BRTO
38	Gastric variceal bleeding and TIPS thrombosis

44% were transfused with fresh frozen plasma. During the same time period, six patients (7%) suffered thrombotic events: 4 had peripheral acute deep vein thrombosis, 1 had acute portal vein thrombosis, and 1 suffered a TIPS thrombosis 7 months after the initial placement of the TIPS. Notably, none of these patients were on subcutaneous heparin prophylaxis. Two patients suffered both a bleeding and a clotting episode during the same hospital admission. One patient was treated acutely for a gastric variceal bleed with TIPS, and subsequently suffered a thrombosis of the shunt. Another patient presented with a gastric variceal bleed and developed a lower extremity deep vein thrombosis.




Figure 1. Transfusion of plasma and platelets in total and in cirrhosis patients. While cirrhosis patients constituted only 7.7% of all patients receiving these blood products in the study intervals, they disproportionately consumed 32% of plasma units ($p < 0.001$ Fisher exact test). Platelet use in cirrhosis was relatively low (13% of total) which is somewhat paradoxical in light of recent laboratory advances in cirrhotic hemostasis as discussed in the text.

Procoagulant blood product use in the outpatient or inpatient liver disease population

A total of 168 patients were transfused with plasma and/or platelets during the three separate days that blood bank records were surveyed. Although there were a total of only 13 cirrhotic patients (7.7%) in the entire sample of transfused patients during these three intervals, liver disease patients consumed 46 of the 142 units of FFP administered (32.4%), and 7 of the 53 units of platelets transfused (13.2%) (Figure 1). Of the cirrhotic patients transfused, 3 of the patients had documented bleeding as the primary indication for transfusion, while the remaining 10 were given products for prophylaxis, 9 for pre-procedural prophylaxis (Table 2). No acute febrile transfusions reactions were documented although one patient with autoimmune liver disease who received prophylactic plasma for dialysis catheter insertion had a chest X-ray consistent with severe pulmonary edema and required mechanical ventilation within 48 hours post-transfusion. Clinically, this suggested TRALI (transfusion-related acute lung injury), but definitive diagnostic studies were not performed.

DISCUSSION

Among 85 consecutive decompensated cirrhosis patients admitted to an inpatient Hepatology Service over a 6 week period, 34 patients (40%) suffered a bleeding episode and 6 patients (7%) suffered deep venous thrombotic disease. Collectively, 50% of

Table 2. Diagnosis, indication, and outcomes for transfused patients.

Patients	Diagnosis	Indication	2 day outcomes
1	Autoimmune	Prophylaxis-Dialysis access	Pulmonary edema-TRALI-Intubated
2	Cryptogenic	Rectal bleeding	Endoscopy
3	Liver failure	Prophylaxis-Central line access	No acute changes
4	Alcoholic hepatitis	Prophylaxis-TIPS revision	No acute changes
5	Hep C, HCC	Prophylaxis-TACE treatment	No acute changes
6	Hep C	Prophylaxis-Pretransplant	Pre-renal acute tubular necrosis
7	Autoimmune	Central line site bleed	No acute changes
8	Cryptogenic	Rectal bleeding	No acute changes
9	Hep C	Prophylaxis-Pretransplant	No acute changes
10	Autoimmune	Prophylaxis-Pretransplant	No acute changes
11	Wilson's	Prophylaxis-Dialysis access	No acute changes
12	HCC	Prophylaxis-Pretransplant	No acute changes
13	Alcoholic hepatitis	Prophylaxis-Knee drainage	No acute changes

HCC: hepatocellular carcinoma. TRALI: transfusion related lung injury.

these admissions had some type of complication related to bleeding or clotting during their hospital stay. In a separate survey, this study confirmed a common clinical suspicion that liver disease patients used a significant and disproportionate amount of procoagulant blood products dispensed from a tertiary care center blood bank. Although liver disease patients constituted 7.7% of all inpatients and outpatients receiving transfusions during the times surveyed, these patients utilized 32% of administered plasma and 13% of platelets. Our work provides a fresh perspective on the magnitude of hemostatic problems in cirrhosis in light of recent laboratory advances.

The fields of hematology and hepatology interface extensively because of the central role of the liver in the synthesis of pro- and anti-coagulation factors and hepatic clearance of by-products of hemostasis and coagulation. As a result, indices of coagulation are an essential part of prognostic scoring systems for advanced liver disease such as the MELD score. Although for many years the coagulopathy of liver disease was felt to result in 'auto-anticoagulation', recent studies have refuted this concept.¹¹ It is now apparent that patients with cirrhosis may be relatively hypercoagulable regardless of conventional indices such as the INR. This situation results from the deficit of liver-derived protein C and increased endothelial-derived factor VIII along with intact endothelial thrombomodulin function. Coagulation is further augmented in cirrhosis through increased von Willebrand factor which enhances platelet adhesion.⁷ Other conditions such as volume overload, renal failure, infection, endothelial dysfunction, or hyperfibrinolysis are often superimposed and result in severe hemostatic instability. In this setting, it is thus not surprising to encounter both bleeding and thrombotic issues in this patient population. In fact, two of the patients included in the study suffered from both a bleeding and clotting event during the same hospital admission. This reinforces the complexity of the hemostatic system in cirrhotic patients.

Measuring the relative risk of bleeding or thrombotic problems in a particular patient is challenging with conventional coagulation indices such as the INR as this test cannot account for the changes in the pro-coagulant pathways discussed above. Reproducibility of this test as conventionally performed for warfarin therapy has also proven to be dependent on commercially prepared thromboplastins (used in the prothrombin time reaction) in

cirrhosis.^{12,13} In spite of these marked limitations, published guidelines have continued to advocate old 'cut-offs' for the INR as relatively more or less safe in the setting of invasive procedures.² This has led to the persistent clinical practice of pre-procedure plasma administration although the efficacy of this strategy is highly questionable and the practice has largely been abandoned as a routine in liver transplant surgery.¹⁴ Nonetheless, this practice accounted for the majority of plasma utilization in our point in time assessment of blood product use in cirrhosis patients.

Our report has several inherent limitations. This was an observational study and although limited outcomes data were available in some aspects of the study, we lacked details on laboratory values, prior bleeding episodes or co-existing conditions such as infection or renal failure. We did not seek to determine predictors of bleeding or clotting in this study. Others have shown that the conventional laboratory based indices (INR for example) are of questionable value in this setting.¹⁵ On the other hand, our aim was to provide a snapshot view of the magnitude of the problems of bleeding and deep vein thrombosis and the impact of hemostatic uncertainties on blood bank utilization in cirrhosis. To this end, our results show that indeed both problems are significant among cirrhosis patients in a tertiary care facility and the impact on blood product utilization remains substantial in spite of advances in the laboratory based understanding of coagulation in liver disease. These results will be useful in the development of further studies aimed at refining clinical strategies for managing hemostasis in cirrhosis.

ABBREVIATIONS

- **FFP:** fresh frozen plasma.
- **TIPS:** transjugular intrahepatic portosystemic shunt.
- **INR:** international normalized ratio.

FUNDING SOURCE

Funding was provided by the University of Virginia, no conflicts of interest exist for Shah, Northup, or Caldwell.

IRB

This study was approved by the University of Virginia Institutional Review Board.

REFERENCES

1. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. *Hepatology* 2002; 36: 227-42.
2. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. *Hepatology* 2006; 44: 1039-46.
3. Mannucci PM. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No. *J Thromb Haemost* 2006; 4: 721-3.
4. Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. *Aliment Pharmacol Ther* 2007; 26: 141-8.
5. Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. *J Hepatol* 2007; 46: 727-33.
6. Northup PG. Hypercoagulation in liver disease. *Clin Liver Dis* 2009; 13: 109-16.
7. Lisman T, Bongers TN, Adelmeijer J, Janssen HLA, De Maat MPM, De Groot PG, Leebeek FWG. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. *Hepatology* 2006; 44: 53-61.
8. Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH, Berg CL. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. *Am J Gastroenterol* 2006; 101: 1524-8.
9. Dabbagh O, Oza A, Prakash S, Sunna R, Saettele TM. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. *Chest* 2010; 137: 1145-9.
10. Sogaard KK, Horvath-Puho E, Gronbaek H, Jepsen P, Vilstrup H, Sorensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. *Am J Gastroenterol* 2009; 104: 96-101.
11. Tripodi A, Primignani M, Chantarangkul V, Dell'Era A, Clerici M, De Franchis R, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. *Gastroenterology* 2009; 137: 2105-11.
12. Trotter JF, Olson J, Lefkowitz J, Smith AD, Arjal R, Kenison J. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. *Am J Transplant* 2007; 7: 1624-8.
13. Lisman T, van Leeuwen Y, Adelmeijer J, Pereboom IT, Haagsma EB, van den Berg AP, Porte RJ. Interlaboratory variability in assessment of the model of end-stage liver disease score. *Liver Int* 2008; 28: 1344-51.
14. Alkozai EM, Lisman T, Porte RJ. Bleeding in liver surgery: prevention and treatment. *Clin Liver Dis* 2009; 13: 145-54.
15. Lisman T, Caldwell SH, Burroughs AK, Northup PG, Senzolo M, Stravitz RT, Tripodi A, et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. *J Hepatol* 2010; 53: 362-71.